HIGHLIGHTS
- who: Matthias P. Hofer and collaborators from the Utrecht University, Netherlands Temple University, United States have published the research work: Regulatory policy and pharmaceutical innovation in the United Kingdom after Brexit: Initial insights, in the Journal: (JOURNAL)
- what: The aim of this study was to analyze the first year of independent regulatory activity by the MHRA in the context of the new vision for pharmaceutical innovation as set out by the UK government and compare it to that of other international regulatory agencies in USA (FDA), EU (EMA) and Switzerland (Swissmedic). The majority of licensing . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.